Found: 17
Select item for more details and to access through your institution.
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 644, doi. 10.1007/s10637-014-0072-y
- By:
- Publication type:
- Article
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1236, doi. 10.1007/s10637-013-9942-y
- By:
- Publication type:
- Article
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 623, doi. 10.1007/s10637-012-9843-5
- By:
- Publication type:
- Article
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Correction notice
A new mathematical approach for the estimation of the AUC and its variability under different experimental designs in preclinical studies.
- Published in:
- Pharmaceutical Statistics, 2012, v. 11, n. 1, p. 14, doi. 10.1002/pst.484
- By:
- Publication type:
- Article
Phase I/II study of weekly PM00104 (Zalypsis<sup>®</sup>) in patients with relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 4, p. 625, doi. 10.1111/bjh.13515
- By:
- Publication type:
- Article
Population Pharmacokinetic‐Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 9, p. 1206, doi. 10.1002/jcph.1886
- By:
- Publication type:
- Article
Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).
- Published in:
- 2012
- By:
- Publication type:
- journal article
Population Pharmacokinetic-Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®).
- Published in:
- Clinical Pharmacokinetics, 2012, v. 51, n. 11, p. 751, doi. 10.1007/s40262-012-0011-z
- By:
- Publication type:
- Article
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 5, p. 585, doi. 10.1007/s00280-021-04366-3
- By:
- Publication type:
- Article
Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase II clinical trial of PM00104 (Zalypsis) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
- Published in:
- 2014
- By:
- Publication type:
- Report
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 6, p. 1557, doi. 10.1007/s00280-012-1864-4
- By:
- Publication type:
- Article
Population pharmacokinetics of PM00104 (Zalypsis) in cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 15, doi. 10.1007/s00280-011-1644-6
- By:
- Publication type:
- Article